Berkshire Hathaway ended 2025 holding about $373.3 billion in cash, the largest corporate cash position in American business history. The engine underneath that number was never stock picking, though that is the part that gets the attention. It was float, the steady recurring cash that insurance premiums throw off before claims come due, which Berkshire used for sixty years to buy good businesses and hold them indefinitely. The genius of the model was never a single brilliant trade. It was a permanent source of low-cost capital paired with the patience to own great assets forever. A small group of permanent-capital firms have spent the last decade looking for the same engine outside insurance. Recurring procedural healthcare cash flow is one of the cleanest analogs that exists, and ophthalmology produces it in volume.

Why Ophthalmology Cash Flow Behaves Like Float

Float is valuable because it is recurring, predictable, and largely indifferent to the business cycle. A cataract is not a discretionary purchase. An aging eye does not wait for a better market or a stronger quarter. The cash flow from cataract surgery, the surgical facility fee that rides alongside it, and the recurring injection economics of retina care all share the quality that makes float powerful, which is that the money arrives on a schedule the demographic curve sets rather than one the stock market sets.

A permanent holder that owns these streams can use them the way Berkshire uses premiums. The recurring cash funds the next acquisition from internal resources rather than from a new fund with a new ten-year clock and a new layer of fees. Each practice acquired throws off cash that helps acquire the next, and because the holder never has to sell, the base of recurring cash flow compounds rather than resetting every time a fund winds down. That is the difference between an engine and a transaction. A fund does a series of transactions and then stops. An engine runs continuously, and the cash flow it produces is the fuel for its own expansion.

How Permanent Capital Already Copies This Model in Ophthalmology-Adjacent Markets

The model is not hypothetical, and the ophthalmology application is not a stretch from what sophisticated capital already does. Cranemere was built in 2014 explicitly as an alternative to traditional private equity, structured around roughly three billion dollars of perpetual equity so that it would never face the pressure to sell winners early or pile on leverage to manufacture a return. Its founders stated the rationale plainly, that the traditional fund model forces managers to sell good businesses too soon because of the fund life cycle and to over-lever them to boost reported returns. Apollo built a comparable engine around Athene's roughly seventy billion dollar base, using long-dated insurance liabilities as a source of patient capital for permanent ownership.

The common thread across all of these vehicles is patient, recurring capital paired with permanent ownership of operating businesses. What none of them did at scale was buy fragmented surgical specialty practices, which is precisely the gap an ophthalmology platform fills. The float analog has been sitting in healthcare the entire time, and most permanent-capital money has been pointed at insurance, at industrials, at consumer brands, at everything except the surgical specialty that produces recurring, demographically driven, recession-resistant cash flow most reliably.

What a Family Office Recognizes in the Ophthalmology Float

A family office reading this recognizes the shape immediately, because it is the shape of their own best holding. Recurring cash flow, pricing power that survives recessions, a fragmented market that rewards a patient consolidator, and an asset worth owning forever rather than flipping in a cycle. The families that built lasting wealth almost always did it by owning one great cash-generating business for a very long time, and they recognize the pattern when they see it again.

Ophthalmology is the float Berkshire never bought, because Berkshire was busy buying insurance and railroads and never turned its attention to fragmented surgical specialty practices. The cash flow was always here, recurring and demographically guaranteed, waiting for an owner who measures hold periods in decades instead of fund cycles. The model that built the largest cash position in American history applies cleanly to a market no one applied it to. That is the opportunity, and it is hiding in plain sight inside a fee schedule and a census table.

Why the Ophthalmology Float Is Cleaner Than the Insurance Kind

The reason the analog holds so well comes down to the quality of the underlying liability, or in this case the absence of one. Insurance float carries the risk that claims exceed premiums in a bad year, which is the discipline that keeps a good underwriter honest and the risk that occasionally sinks a careless one. Procedural healthcare cash flow carries no equivalent claim risk, because the patient pays for a service already rendered rather than insuring against a future loss. The recurring revenue arrives without the tail risk that makes insurance float complex to manage. A permanent holder of ophthalmology cash flow gets the recurring, low-cyclicality funding source that makes the Berkshire model work, without the underwriting risk that sits underneath it.

The honest counterargument is that healthcare cash flow carries its own risks that insurance float does not, and an allocator should weigh them rather than wave them away. Reimbursement rates can be cut, regulatory structures can change, and a practice depends on physicians who can leave. These are real, and they are the reasons the model requires a compliant structure, a successor-physician pipeline, and diversification across practices rather than dependence on a single surgeon. What they do not do is introduce the catastrophic tail risk that defines insurance, where a single bad year of claims can erase years of float. A cut to a reimbursement rate trims a margin. It does not vaporize the asset. The risks in healthcare cash flow are manageable operating risks, not existential underwriting risks, which is precisely what makes the float analog cleaner rather than merely equivalent.

For a family office evaluating where to find patient capital's version of an engine, that is a cleaner version of the same machine, pointed at a market with fifteen years of demographic tailwind in front of it. The families that built the great permanent-capital fortunes understood that the rarest and most valuable thing in investing is a recurring, low-risk source of cash that funds the next acquisition without raising outside money. Berkshire found it in insurance. Cranemere and Apollo found versions of it in perpetual equity and long-dated liabilities. The version sitting in ophthalmology has been overlooked not because it is inferior, but because the capital best suited to use it was looking everywhere else.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com